Drug intelligence / Profile preview

MegaLT

Development stage: Phase 1
Lead developer: The First Affiliated Hospital of USTC
Modality: Cell Therapies
Administration: Injection

Overview

MegaLT is an allogeneic megakaryocyte (MK) product, specifically an ex vivo three-dimensional induced umbilical cord blood mononuclear cells differentiated megakaryocyte injection. It is being developed for treating refractory thrombocytopenia following radiotherapy, chemotherapy, or transplantation. Its mechanism involves providing megakaryocytes, which are precursor cells for platelet production, to improve platelet counts. It is administered as an injection. It is described as an off-the-shelf, cryopreserved allogeneic MK product.

Beyond the preview

Go deeper on MegaLT.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MegaLT.

Explore the full profile